Late-stage Resectable Esophageal Squamous CarcinomaPhase 2NCT07622797
Exploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy as an Organ-preserving Strategy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
A Phase 2 study testing Camrelizumab (anti-PD-1 inhibitor), Albumin-Bound Paclitaxel /nab-Paclitaxel and Carboplatin in people with Late-stage Resectable Esophageal Squamous Carcinoma, run by The First Affiliated Hospital of Henan University of Science and Technology at 1 site in China.
Trial summary
This study is a prospective, exploratory clinical study aimed at evaluating the feasibility and safety of camrelizumab combined with synchronous chemoradiotherapy as an organ-preserving strategy for locally advanced resectable esophageal squamous cell carcinoma. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Late-stage Resectable Esophageal Squamous Carcinoma
- What is being tested?
- Camrelizumab (anti-PD-1 inhibitor), Albumin-Bound Paclitaxel /nab-Paclitaxel and Carboplatin
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 164 participants
- Where
- 1 siteChina
- Study dates
- 21 Nov 2025to 31 Dec 2030
- Phase
- Phase 2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- 1. Age ≥18 years old; 2. Histologically or cytologically confirmed esophageal squamous cell carcinoma (ESCC); 3. Patients with locally advanced resectable stage II/III/IVa (cT1b-4aN0-3M0) ESCC; 4. Have not received chemotherapy, radiotherapy, or surgical treatment for esophageal cancer; 6. ECOG performance status: 0-1; 7. Expected survival ≥12 weeks; 8. Within 7 days prior to enrollment, the participant's blood routine and biochemical indicators meet the following criteria:
- Hemoglobin ≥90 g/L; absolute neutrophil count (ANC) ≥1.5 × 10^9/L; platelets ≥100 × 10^9/L (patients must not have received blood transfusion or growth factor support within 14 days before blood sampling);
- ALT and AST ≤2.5 times the upper limit of normal (ULN); ALP ≤2.5 times ULN;
- Total serum bilirubin <1.5 times ULN (patients with Gilbert's syndrome may enroll if total bilirubin <3 times ULN);
- Serum creatinine <1.5 times ULN or estimated glomerular filtration rate ≥60 ml/min/1.73 m²;
- Serum albumin ≥30 g/L;
Show all 11Show fewer
- International normalized ratio (INR) or prothrombin time (PT) ≤1.5 times ULN, unless the patient is on anticoagulant therapy and PT value is within the expected therapeutic range;
- Activated partial thromboplastin time (APTT) ≤1.5 times ULN. 9. Doppler ultrasound assessment: Left ventricular ejection fraction (LVEF) ≥ lower limit of normal (50%).
- 10. Women of childbearing potential must agree to use contraceptive measures (such as intrauterine device, contraceptive pills, or condoms) during the study and for 6 months after the study; must have a negative serum or urine pregnancy test within 7 days prior to study enrollment, and must not be breastfeeding; men must agree to use contraceptive measures during the study and for 6 months after the study.
- 11. No severe comorbidities that would result in a life expectancy of less than 5 years.
- 12. Subjects voluntarily participate in this study, sign the informed consent form, have good compliance, and cooperate with follow-up.
Who cannot join
- 1. Individuals allergic to the treatment drugs; 2. History of organ transplantation (including autologous bone marrow transplantation and peripheral stem cell transplantation); 3. Active or uncontrolled severe infection (≥ CTCAE5.0 grade 2 infection), including but not limited to hospitalization due to infection complications, bacteremia, or severe pneumonia, or unexplained fever >38.5°C before the first administration; 4. Individuals with a history of mental drug abuse who cannot quit or have psychiatric disorders; 5. Subjects who have had or currently have other malignancies requiring active treatment within the past 5 years (fully treated cases with an expected 5-year survival >90%, such as basal cell or squamous cell skin cancer, cervical carcinoma in situ, or breast carcinoma in situ, are excluded from this restriction); 6. Uncorrectable coagulation disorders; 7. Clinically significant cardiovascular diseases, including but not limited to acute myocardial infarction, severe/unstable angina, or coronary artery bypass surgery within 6 months prior to enrollment; congestive heart failure NYHA class ≥2; ventricular arrhythmias requiring drug treatment (including QTc interval ≥450 ms for men, ≥470 ms for women); left ventricular ejection fraction (LVEF) <50%; 8. Severe liver disease (such as cirrhosis), kidney disease, respiratory system disease, uncontrolled diabetes, or other types of systemic diseases; 9. Patients whose imaging shows the tumor has invaded major blood vessels, or for whom the investigator judges that the tumor is highly likely to invade major blood vessels during the study period and cause fatal bleeding; 10. Presence of active autoimmune disease or immunodeficiency, or the following history, including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, rheumatoid arthritis, inflammatory bowel disease, hypophysitis, vasculitis, nephritis, etc. The following exceptions apply: patients with a history of autoimmune hypothyroidism who are receiving thyroid hormone replacement therapy may be enrolled. Patients with type 1 diabetes whose blood glucose is controlled after insulin therapy may participate in this study.
- 11. Patients who are using immunosuppressive agents or systemic corticosteroid therapy for immunosuppression purposes (dose >10 mg/day of prednisone or other equivalent steroids, and continued use within 2 weeks prior to enrollment); 14. Underwent surgery within 28 days before enrollment in this study (excluding biopsy) or whose surgical incision has not fully healed; 15. Received any other investigational drug treatment or participated in other interventional studies within 4 weeks prior to signing the informed consent; 16. Pregnant women (positive pregnancy test before taking the drug) or women who are breastfeeding; 17. Patients deemed unsuitable for enrollment based on the investigator's judgment.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
The First Affiliated Hospital of Henan University of Science and Technology
Luoyang, Henan, 471000
Jun Li, +86 13653883920, hkdyfyllb@163.com
About this study
This study is a prospective, exploratory clinical study aimed at evaluating the feasibility and safety of camrelizumab combined with synchronous chemoradiotherapy as an organ-preserving strategy for locally advanced resectable esophageal squamous cell carcinoma.
The study targets patients with locally advanced resectable stage II/III/IVa (cT1b-4aN0-3M0) ESCC. A total of 164 subjects are expected to be enrolled.
Read more
The study is a randomized, non-controlled, open-label trial. Subjects meeting the inclusion criteria will be randomly assigned in a 1:1 ratio to receive either camrelizumab combined with radiotherapy, albumin-bound paclitaxel, and carboplatin treatment (Cohort 1) or camrelizumab combined with radiotherapy and capecitabine treatment (Cohort 2).
The screening period for the study is 28 days. After completing screening examinations and assessments, eligible subjects will be randomly assigned to the following treatment regimens.
Cohort 1:
- Camrelizumab: 200 mg on Day 1, every 3 weeks
- Radiotherapy: 50-50.4 Gy / 25-28 fractions, Days 1-5, once a week
- Albumin-bound paclitaxel: IV infusion, 60-80 mg/m², Day 1, weekly
- Carboplatin: IV infusion, AUC=1-1.5, Day 1, weekly
Each cycle lasts 3 weeks, with 2-4 cycles of medication.
Efficacy evaluation (imaging and endoscopic examination) will be conducted within 6 weeks after the completion of treatment. If the efficacy evaluation indicates cCR, subjects will enter Group A1 and receive camrelizumab maintenance therapy (maximum 1 year). If the efficacy evaluation does not reach cCR, after consultation between the investigator and the subject, they will enter Group B1 to undergo radical surgery, followed by camrelizumab monotherapy maintenance treatment (maximum 1 year).
Cohort 2:
Camrelizumab: ivgtt, 200 mg, D1, Q3W Radiotherapy: 50-50.4 Gy / 25-28 fractions, D1-D5, QW Capecitabine: p.o. 625 mg/m², BID, D1-D14, Q3W; One cycle lasts 3 weeks, with 2-4 cycles of medication. Efficacy evaluation (imaging and endoscopy) will be conducted within 6 weeks after treatment completion. If the efficacy is assessed as cCR, the patient will enter Group A2: receive camrelizumab maintenance therapy (up to 1 year); if efficacy is not cCR, the patient will enter Group B2: undergo radical surgery, followed by camrelizumab monotherapy maintenance (up to 1 year).
This study will follow up subjects for disease recurrence and disease-free survival for at least 2 years. After all subjects complete the treatment/termination visit, efficacy will be evaluated.
- Being tested
- Camrelizumab (anti-PD-1 inhibitor), Albumin-Bound Paclitaxel /nab-Paclitaxel, Carboplatin, Capecitabine, radiotherapy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Camrelizumab (anti-PD-1 inhibitor)Drug
200 mg, Day 1, every 3 weeks ,One cycle lasts 3 weeks, with 2-4 cycles of medication.
Albumin-Bound Paclitaxel /nab-PaclitaxelDrug
IV infusion, 60-80 mg/m², Day 1, weekly;One cycle lasts 3 weeks, with 2-4 cycles of medication.
CarboplatinDrug
IV infusion, AUC=1-1.5, Day 1, weekly ;One cycle lasts 3 weeks, with 2-4 cycles of medication.
CapecitabineDrug
p.o. 625 mg/m², BID, D1-D14, Q3W; One cycle is 3 weeks, with 2-4 cycles of medication.
radiotherapyRadiation
50-50.4 Gy / 25-28 fractions, D1-D5, QW ,One cycle is 3 weeks, with 2-4 cycles of medication.
| Study group | Role | What they receive |
|---|---|---|
| Camrelizumab+Radiotherapy+Albumin-bound paclitaxel+Carboplatin | Experimental | Not described Receives: Drug: Camrelizumab (anti-PD-1 inhibitor); Drug: Albumin-Bound Paclitaxel /nab-Paclitaxel; Drug: Carboplatin; Radiation: radiotherapy |
| Carrellizumab+Radiotherapy+Capecitabine | Experimental | Not described Receives: Drug: Camrelizumab (anti-PD-1 inhibitor); Drug: Capecitabine; Radiation: radiotherapy |
What is being measured
The primary outcome is the main question the study is designed to answer.
2-year OS rate
Measured: 2-year
Secondary outcomes (5)
2-year EFS rate
Measured: 2-year
cCR rate
Measured: 18 weeks
Median EFS
Measured: 5 years
Median overall survival
Measured: 5 years
AE incidence
Measured: 18 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted3 Jun 2026
- Study start21 Nov 2025
- Primary completion31 Dec 2028 (estimated)
- Study completion31 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Late-stage Resectable Esophageal Squamous CarcinomaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 164 participants (estimated)
Sponsor and investigators
- Lead sponsor
- The First Affiliated Hospital of Henan University of Science and Technology
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Shan TY, The First Affiliated Hospital of Henan University of Science and Technology
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07622797
- Sponsor's protocol ID
- CAM-ESCC-OP-01
- Status last verified
- May 2026
- First submitted
- 28 May 2026
- Last updated
- 3 Jun 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 3 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Exploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy as an Organ-preserving Strategy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
- ClinicalTrials.gov ID
- NCT07622797
- Acronym / sponsor ID
- CAM-ESCC-OP-01
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 164 participants (estimated)
- Lead sponsor
- The First Affiliated Hospital of Henan University of Science and TechnologyUniversity, hospital or other
- Study start
- 21 Nov 2025 (actual)
- Primary completion
- 31 Dec 2028 (estimated)
- Study completion
- 31 Dec 2030 (estimated)
- First posted
- 3 Jun 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study is a prospective, exploratory clinical study aimed at evaluating the feasibility and safety of camrelizumab combined with synchronous chemoradiotherapy as an organ-preserving strategy for locally advanced resectable esophageal squamous cell carcinoma.
The study targets patients with locally advanced resectable stage II/III/IVa (cT1b-4aN0-3M0) ESCC. A total of 164 subjects are expected to be enrolled.
The study is a randomized, non-controlled, open-label trial. Subjects meeting the inclusion criteria will be randomly assigned in a 1:1 ratio to receive either camrelizumab combined with radiotherapy, albumin-bound paclitaxel, and carboplatin treatment (Cohort 1) or camrelizumab combined with radiotherapy and capecitabine treatment (Cohort 2).
The screening period for the study is 28 days. After completing screening examinations and assessments, eligible subjects will be randomly assigned to the following treatment regimens.
Cohort 1:
- Camrelizumab: 200 mg on Day 1, every 3 weeks
- Radiotherapy: 50-50.4 Gy / 25-28 fractions, Days 1-5, once a week
- Albumin-bound paclitaxel: IV infusion, 60-80 mg/m², Day 1, weekly
- Carboplatin: IV infusion, AUC=1-1.5, Day 1, weekly
Each cycle lasts 3 weeks, with 2-4 cycles of medication.
Efficacy evaluation (imaging and endoscopic examination) will be conducted within 6 weeks after the completion of treatment. If the efficacy evaluation indicates cCR, subjects will enter Group A1 and receive camrelizumab maintenance therapy (maximum 1 year). If the efficacy evaluation does not reach cCR, after consultation between the investigator and the subject, they will enter Group B1 to undergo radical surgery, followed by camrelizumab monotherapy maintenance treatment (maximum 1 year).
Cohort 2:
Camrelizumab: ivgtt, 200 mg, D1, Q3W Radiotherapy: 50-50.4 Gy / 25-28 fractions, D1-D5, QW Capecitabine: p.o. 625 mg/m², BID, D1-D14, Q3W; One cycle lasts 3 weeks, with 2-4 cycles of medication. Efficacy evaluation (imaging and endoscopy) will be conducted within 6 weeks after treatment completion. If the efficacy is assessed as cCR, the patient will enter Group A2: receive camrelizumab maintenance therapy (up to 1 year); if efficacy is not cCR, the patient will enter Group B2: undergo radical surgery, followed by camrelizumab monotherapy maintenance (up to 1 year).
This study will follow up subjects for disease recurrence and disease-free survival for at least 2 years. After all subjects complete the treatment/termination visit, efficacy will be evaluated.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Camrelizumab+Radiotherapy+Albumin-bound paclitaxel+Carboplatin | Experimental | Drug: Camrelizumab (anti-PD-1 inhibitor), Drug: Albumin-Bound Paclitaxel /nab-Paclitaxel, Drug: Carboplatin, Radiation: radiotherapy |
| Carrellizumab+Radiotherapy+Capecitabine | Experimental | Drug: Camrelizumab (anti-PD-1 inhibitor), Drug: Capecitabine, Radiation: radiotherapy |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (11 listed)
- 1. Age ≥18 years old; 2. Histologically or cytologically confirmed esophageal squamous cell carcinoma (ESCC); 3. Patients with locally advanced resectable stage II/III/IVa (cT1b-4aN0-3M0) ESCC; 4. Have not received chemotherapy, radiotherapy, or surgical treatment for esophageal cancer; 6. ECOG performance status: 0-1; 7. Expected survival ≥12 weeks; 8. Within 7 days prior to enrollment, the participant's blood routine and biochemical indicators meet the following criteria:
- 10. Women of childbearing potential must agree to use contraceptive measures (such as intrauterine device, contraceptive pills, or condoms) during the study and for 6 months after the study; must have a negative serum or urine pregnancy test within 7 days prior to study enrollment, and must not be breastfeeding; men must agree to use contraceptive measures during the study and for 6 months after the study.
- 11. No severe comorbidities that would result in a life expectancy of less than 5 years.
- 12. Subjects voluntarily participate in this study, sign the informed consent form, have good compliance, and cooperate with follow-up.
Key exclusion criteria (2 listed)
- 1. Individuals allergic to the treatment drugs; 2. History of organ transplantation (including autologous bone marrow transplantation and peripheral stem cell transplantation); 3. Active or uncontrolled severe infection (≥ CTCAE5.0 grade 2 infection), including but not limited to hospitalization due to infection complications, bacteremia, or severe pneumonia, or unexplained fever >38.5°C before the first administration; 4. Individuals with a history of mental drug abuse who cannot quit or have psychiatric disorders; 5. Subjects who have had or currently have other malignancies requiring active treatment within the past 5 years (fully treated cases with an expected 5-year survival >90%, such as basal cell or squamous cell skin cancer, cervical carcinoma in situ, or breast carcinoma in situ, are excluded from this restriction); 6. Uncorrectable coagulation disorders; 7. Clinically significant cardiovascular diseases, including but not limited to acute myocardial infarction, severe/unstable angina, or coronary artery bypass surgery within 6 months prior to enrollment; congestive heart failure NYHA class ≥2; ventricular arrhythmias requiring drug treatment (including QTc interval ≥450 ms for men, ≥470 ms for women); left ventricular ejection fraction (LVEF) <50%; 8. Severe liver disease (such as cirrhosis), kidney disease, respiratory system disease, uncontrolled diabetes, or other types of systemic diseases; 9. Patients whose imaging shows the tumor has invaded major blood vessels, or for whom the investigator judges that the tumor is highly likely to invade major blood vessels during the study period and cause fatal bleeding; 10. Presence of active autoimmune disease or immunodeficiency, or the following history, including but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, rheumatoid arthritis, inflammatory bowel disease, hypophysitis, vasculitis, nephritis, etc. The following exceptions apply: patients with a history of autoimmune hypothyroidism who are receiving thyroid hormone replacement therapy may be enrolled. Patients with type 1 diabetes whose blood glucose is controlled after insulin therapy may participate in this study.
- 11. Patients who are using immunosuppressive agents or systemic corticosteroid therapy for immunosuppression purposes (dose >10 mg/day of prednisone or other equivalent steroids, and continued use within 2 weeks prior to enrollment); 14. Underwent surgery within 28 days before enrollment in this study (excluding biopsy) or whose surgical incision has not fully healed; 15. Received any other investigational drug treatment or participated in other interventional studies within 4 weeks prior to signing the informed consent; 16. Pregnant women (positive pregnancy test before taking the drug) or women who are breastfeeding; 17. Patients deemed unsuitable for enrollment based on the investigator's judgment.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Camrelizumab (anti-PD-1 inhibitor)200 mg, Day 1, every 3 weeks ,One cycle lasts 3 weeks, with 2-4 cycles of medication. | Drug | Camrelizumab+Radiotherapy+Albumin-bound paclitaxel+Carboplatin, Carrellizumab+Radiotherapy+Capecitabine |
| Albumin-Bound Paclitaxel /nab-PaclitaxelIV infusion, 60-80 mg/m², Day 1, weekly;One cycle lasts 3 weeks, with 2-4 cycles of medication. | Drug | Camrelizumab+Radiotherapy+Albumin-bound paclitaxel+Carboplatin |
| CarboplatinIV infusion, AUC=1-1.5, Day 1, weekly ;One cycle lasts 3 weeks, with 2-4 cycles of medication. | Drug | Camrelizumab+Radiotherapy+Albumin-bound paclitaxel+Carboplatin |
| Capecitabinep.o. 625 mg/m², BID, D1-D14, Q3W; One cycle is 3 weeks, with 2-4 cycles of medication. | Drug | Carrellizumab+Radiotherapy+Capecitabine |
| radiotherapy50-50.4 Gy / 25-28 fractions, D1-D5, QW ,One cycle is 3 weeks, with 2-4 cycles of medication. | Radiation | Camrelizumab+Radiotherapy+Albumin-bound paclitaxel+Carboplatin, Carrellizumab+Radiotherapy+Capecitabine |
Primary outcome
2-year OS rate
Time frame: 2-year
5 secondary outcomes
2-year EFS rate
Time frame: 2-year
cCR rate
Time frame: 18 weeks
Median EFS
Time frame: 5 years
Median overall survival
Time frame: 5 years
AE incidence
Time frame: 18 weeks
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 3 Jun 2026.
Related trials for Late-stage Resectable Esophageal Squamous Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Camrelizumab (anti-PD-1 inhibitor), Albumin-Bound Paclitaxel /nab-Paclitaxel and Carboplatin in people with Late-stage Resectable Esophageal Squamous Carcinoma, run by The First Affiliated Hospital of Henan University of Science and Technology at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 11 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 3 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ruinuo Jia (+86 185 3795 0766, jiaruinuo@163.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
2-year OS rate (time frame: 2-year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jun 2026.